What are major Oncology combination therapies based on claims data?
In Oncology
Get Dexur’s Personalized Hospital Specific Presentation on Quality, Safety, Compliance & Education
By: Avinash Kumar May. 01, 2019
Dexur analyzed Medicare claims data based on a 5% sample for the time period of Jan 2016 to June 2018, to understand the prevalence of oncology combination therapies. This methodology checked for relevant J codes of HCPCS code set in the claim files across the patient’s history. If a patient used a base drug, it was then checked to see what other drugs were used on the same patient.
The three highest combinations of drugs were Herceptin & Perjeta (37.04%), Alimta & Opdivo (21%), Keytruda & Alimta (18.13%). Herceptin was used in combination with Perjeta across the treatment journey in 37% of Herceptin patients. Other drugs used in combination with Herceptin are Kadcyla in 8.86% of patients, and Faslodex in 6.67% of patients at any given day. Opdivo was used in Alimta patients 21.07% of the time. Whereas Alimta was used in Opdivo patients 15.11% of the time.
The analysis also shows that, Avastin was the most used drug in Oncology treatment for Medicare patients based on J Codes. However, it is less used in combination therapies, when it is a base drug. Top combination drugs used with Avastin are Alimta, Opdivo and Vectibix, with 2.26%, 1.24% and 0.66% patients treated respectively.
Other notable combinations included Velcade & Kyprolis (12.21%), Faslodex & Herceptin (7.79%) & Abraxane & Opdivo (7.75%).
The top 10 drugs that were studied based on Medicare J codes were:
AVASTIN - INJECTION, BEVACIZUMAB, 10 MG - J9035
RITUXAN - INJECTION, RITUXIMAB, 100 MG - J9310
TICE BCG - BCG (INTRAVESICAL) PER INSTILLATION - J9031
OPDIVO - INJECTION, NIVOLUMAB, 1 MG - J9299
ALIMTA - INJECTION, PEMETREXED, 10 MG - J9305
KEYTRUDA - INJECTION, PEMBROLIZUMAB, 1 MG - J9271
ABRAXANE - INJECTION, PACLITAXEL PROTEIN-BOUND PARTICLES, 1 MG - J9264
VELCADE - INJECTION, BORTEZOMIB (VELCADE), 0.1 MG - J9041
HERCEPTIN - INJECTION, TRASTUZUMAB, 10 MG - J9355
FASLODEX - INJECTION, FULVESTRANT, 25 MG - J9395
DEXUR PRO MEMBERS:
Dexur Pro members gets access to claims count, top ranked drugs and their combinations data. It also provides a breakdown on disease level data, such as - breast cancer, lung cancer prostate cancer and other indication.
Further, ICD level analysis and quarter over quarter analysis are also available for our research subscribers. Email dexur@dexur.com for details on Oncology drug combination therapies and detailed claims level analysis for the drug of your interest.
ABOUT THE AUTHOR
